文献速递骨软组织肉瘤与黑色素瘤

卡瑞利珠单抗联合阿帕替尼与替莫唑胺一线治疗晚期肢端黑色素瘤:CAP 03 2期非随机临床试验

Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

这项单臂、单中心2期非随机临床试验纳入50例未接受过治疗的不可切除III期或IV期肢端黑色素瘤患者,接受卡瑞利珠单抗、阿帕替尼和替莫唑胺治疗。客观缓解率为64.0%(32/50,95%CI 49.2%-77.1%),中位无进展生存期估计为18.4个月(95%CI 10.6至未达到),中位总生存期未达到。作者认为该方案可能为潜在一线选择,但需随机临床试验进一步验证。

要点

  • 客观缓解率64.0%(32/50,95%CI 49.2%-77.1%),疾病控制率88.0%(44/50,95%CI 75.7%-95.5%)。
  • 估计中位无进展生存期18.4个月(95%CI 10.6至未达到),中位总生存期未达到。
  • 常见3或4级治疗相关不良事件为γ-谷氨酰转移酶升高(15例[30%])等,无治疗相关死亡。

核心结论

  • 作者认为卡瑞利珠单抗联合阿帕替尼与替莫唑胺可能为晚期肢端黑色素瘤的潜在一线治疗选择,但需随机临床试验进一步验证。

研究设计与样本

  • 单臂、单中心、2期非随机临床试验,于北京大学肿瘤医院及研究所入组未经治疗的不可切除III期或IV期肢端黑色素瘤患者,入组时间为2020年6月4日至2021年8月24日,数据截止日期为2022年4月10日。
  • 共50例患者(男性32例[64%];中位年龄57岁[IQR 52-62岁])入组并接受治疗,中位随访时间13.4个月(IQR 9.6-16.2个月)。
  • 治疗方案为4周一个周期:静脉卡瑞利珠单抗200 mg每2周一次;口服阿帕替尼250 mg每日一次;静脉替莫唑胺200 mg/m2每日一次,第1至5天给药,直至疾病进展或不可接受的毒性反应。

主要发现

  • 客观缓解率为64.0%(32/50;95%CI 49.2%-77.1%)。
  • 中位至缓解时间和中位缓解持续时间分别为2.7个月(IQR 0.9-2.9个月)和17.5个月(95%CI 12.0至未达到)。
  • 疾病控制率为88.0%(44/50;95%CI 75.7%-95.5%)。
  • 估计中位无进展生存期为18.4个月(95%CI 10.6至未达到),中位总生存期未达到。
  • 最常见的3或4级治疗相关不良事件为γ-谷氨酰转移酶升高(15例[30%])、中性粒细胞计数降低(11例[22%])、结合胆红素升高(10例[20%])和天冬氨酸氨基转移酶升高(10例[20%]),无治疗相关死亡。

关键数值与推荐

  • 主要终点为研究者根据实体瘤疗效评价标准(版本1.1)评估的客观缓解率。
  • 次要终点包括无进展生存期、至缓解时间、缓解持续时间、疾病控制率、总生存期和安全性。

临床怎么用

  • 原文结论指出卡瑞利珠单抗联合阿帕替尼与替莫唑胺可能为晚期肢端黑色素瘤的潜在一线治疗选择,但需随机临床试验进一步验证。

局限性

  • 原文结论指出该发现需在随机临床试验中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Acral melanoma, known for low tumor mutation burden, responds poorly to immunotherapy. A standard therapy is still lacking. OBJECTIVE: To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma. DESIGN, SETTING, AND PARTICIPANTS: In this single-arm, single-center, phase 2 nonrandomized clinical trial, patients with treatment-naive unresectable stage III or IV acral melanoma were enrolled at Peking University Cancer Hospital and Institute between June 4, 2020, and August 24, 2021. The data cutoff date was April 10, 2022. INTERVENTIONS: Patients received 4-week cycles of intravenous camrelizumab, 200 mg, every 2 weeks; oral apatinib 250 mg, once daily; and intravenous temozolomide, 200 mg/m2, once daily on days 1 to 5 until disease progression or unacceptable toxic effects. MAIN OUTCOMES AND MEASURES: The primary end point was objective response rate as assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (version 1.1). Secondary end points included progression-free survival, time to response, duration of response, disease control rate, overall survival, and safety. RESULTS: A total of 50 patients (32 men [64%]; median age, 57 years [IQR, 52-62 years]) were enrolled and received treatment. The median follow-up duration was 13.4 months (IQR, 9.6-16.2 months). The objective response rate was 64.0% (32 of 50; 95% CI, 49.2%-77.1%). The median time to response and duration of response were 2.7 months (IQR, 0.9-2.9 months) and 17.5 months (95% CI, 12.0 to not reached), respectively. The disease control rate was 88.0% (44 of 50; 95% CI, 75.7%-95.5%). The estimated median progression-free survival was 18.4 months (95% CI, 10.6 to not reached). The median overall survival was not reached. The most common grade 3 or 4 treatment-related adverse events were increased gamma-glutamyltransferase levels (15 [30%]), decreased neutrophil count (11 [22%]), increased conjugated bilirubin levels (10 [20%]), and increased aspartate aminotransferase levels (10 [20%]). No treatment-related deaths occurred. CONCLUSIONS AND RELEVANCE: The findings of this nonrandomized clinical trial suggest that camrelizumab plus apatinib and temozolomide may be a potential first-line treatment option for patients with advanced acral melanoma, which warrants further validation in a randomized clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04397770.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mao L, Lian B, Li C, et al. Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2023. PMID: 37261804. doi:10.1001/jamaoncol.2023.1363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。